Oracle Buys Drug Trial Software Firm (ORCL)

Photo of Paul Ausick
By Paul Ausick Published

Oracle Corp. (NASDAQ: ORCL) has announced that it will acquire ClearTrial, a maker of cloud-based Clinical Trial Operations applications for an undisclosed sum. The transaction is expected to close in the first half of this year. The companies will continue to operate separately until the transaction is closed according to the Oracle announcement.

ClearTrial’s clinical trial applications “will add leading budgeting, forecasting, and analytics capabilities that help plan, source, and track clinical projects,” according to an Oracle overview of the transaction. Oracle plans to integrate ClearTrial’s solutions into its Health Sciences applications portfolio.

Oracle shares are trading down fractionally at $29.34 in a 52-week range of $24.72-$36.50.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

BLDR Vol: 2,430,629
IQV Vol: 1,071,085
BKNG Vol: 8,835,677
MHK Vol: 782,522
CRL Vol: 563,005

Top Losing Stocks

CTRA Vol: 73,319,495
WDC Vol: 8,831,902
STX Vol: 2,813,266
APO Vol: 4,145,582
BX Vol: 4,542,406